---
keywords:
  - Sequence-Structure Generative Model
  - Antibody-Antigen Complexes
  - Iterative Antibody Optimization
  - Guided Sampling
category: cs.LG
publish_date: 2025-09-23
arxiv_id: 2509.16357
---

<!-- KEYWORD_LINKING_METADATA:
{
  "processed_timestamp": "2025-09-24T01:35:07.387034",
  "vocabulary_version": "1.0",
  "selected_keywords": [
    "Sequence-Structure Generative Model",
    "Antibody-Antigen Complexes",
    "Iterative Antibody Optimization",
    "Guided Sampling"
  ],
  "rejected_keywords": [],
  "similarity_scores": {
    "Sequence-Structure Generative Model": 0.78,
    "Antibody-Antigen Complexes": 0.82,
    "Iterative Antibody Optimization": 0.75,
    "Guided Sampling": 0.77
  },
  "extraction_method": "AI_prompt_based",
  "budget_applied": true,
  "candidates_json": {
    "candidates": [
      {
        "surface": "sequence-structure diffusion generative model",
        "canonical": "Sequence-Structure Generative Model",
        "aliases": [
          "diffusion generative model"
        ],
        "category": "unique_technical",
        "rationale": "This model is central to the paper's methodology and represents a novel approach combining sequence and structure data.",
        "novelty_score": 0.75,
        "connectivity_score": 0.68,
        "specificity_score": 0.82,
        "link_intent_score": 0.78
      },
      {
        "surface": "antibody-antigen complexes",
        "canonical": "Antibody-Antigen Complexes",
        "aliases": [
          "antibody complexes"
        ],
        "category": "specific_connectable",
        "rationale": "Key biological entities in the study, crucial for understanding the optimization process described.",
        "novelty_score": 0.55,
        "connectivity_score": 0.79,
        "specificity_score": 0.8,
        "link_intent_score": 0.82
      },
      {
        "surface": "iterative antibody optimization",
        "canonical": "Iterative Antibody Optimization",
        "aliases": [
          "antibody optimization"
        ],
        "category": "unique_technical",
        "rationale": "Describes the iterative process central to the paper's research focus.",
        "novelty_score": 0.7,
        "connectivity_score": 0.65,
        "specificity_score": 0.78,
        "link_intent_score": 0.75
      },
      {
        "surface": "guided sampling approach",
        "canonical": "Guided Sampling",
        "aliases": [
          "sampling approach"
        ],
        "category": "unique_technical",
        "rationale": "A novel technique introduced in the paper for optimizing antibody properties.",
        "novelty_score": 0.68,
        "connectivity_score": 0.72,
        "specificity_score": 0.76,
        "link_intent_score": 0.77
      }
    ],
    "ban_list_suggestions": [
      "therapeutic",
      "clinical development",
      "in vitro experiments"
    ]
  },
  "decisions": [
    {
      "candidate_surface": "sequence-structure diffusion generative model",
      "resolved_canonical": "Sequence-Structure Generative Model",
      "decision": "linked",
      "scores": {
        "novelty": 0.75,
        "connectivity": 0.68,
        "specificity": 0.82,
        "link_intent": 0.78
      }
    },
    {
      "candidate_surface": "antibody-antigen complexes",
      "resolved_canonical": "Antibody-Antigen Complexes",
      "decision": "linked",
      "scores": {
        "novelty": 0.55,
        "connectivity": 0.79,
        "specificity": 0.8,
        "link_intent": 0.82
      }
    },
    {
      "candidate_surface": "iterative antibody optimization",
      "resolved_canonical": "Iterative Antibody Optimization",
      "decision": "linked",
      "scores": {
        "novelty": 0.7,
        "connectivity": 0.65,
        "specificity": 0.78,
        "link_intent": 0.75
      }
    },
    {
      "candidate_surface": "guided sampling approach",
      "resolved_canonical": "Guided Sampling",
      "decision": "linked",
      "scores": {
        "novelty": 0.68,
        "connectivity": 0.72,
        "specificity": 0.76,
        "link_intent": 0.77
      }
    }
  ]
}
-->

# Guided Sequence-Structure Generative Modeling for Iterative Antibody Optimization

## ğŸ“‹ ë©”íƒ€ë°ì´í„°

**Links**: [[daily_digest_20250923|20250923]] [[categories/cs.LG|cs.LG]]
**PDF**: [Download](https://arxiv.org/pdf/2509.16357.pdf)
**Category**: cs.LG
**Published**: 2025-09-23
**ArXiv ID**: [2509.16357](https://arxiv.org/abs/2509.16357)

## ğŸ”— ìœ ì‚¬í•œ ë…¼ë¬¸
- [[2025-09-18/Structure-Aware Contrastive Learning with Fine-Grained Binding Representations for Drug Discovery_20250918|Structure-Aware Contrastive Learning with Fine-Grained Binding Representations for Drug Discovery]] (81.6% similar)
- [[2025-09-23/$\texttt{DiffSyn}$_ A Generative Diffusion Approach to Materials Synthesis Planning_20250923|$\texttt{DiffSyn}$: A Generative Diffusion Approach to Materials Synthesis Planning]] (78.6% similar)
- [[2025-09-22/Monte Carlo Tree Diffusion with Multiple Experts for Protein Design_20250922|Monte Carlo Tree Diffusion with Multiple Experts for Protein Design]] (78.6% similar)
- [[2025-09-22/An Equivariant Graph Network for Interpretable Nanoporous Materials Design_20250922|An Equivariant Graph Network for Interpretable Nanoporous Materials Design]] (76.8% similar)
- [[2025-09-22/Rethinking Molecule Synthesizability with Chain-of-Reaction_20250922|Rethinking Molecule Synthesizability with Chain-of-Reaction]] (76.7% similar)

## ğŸ·ï¸ ì¹´í…Œê³ ë¦¬í™”ëœ í‚¤ì›Œë“œ
**ğŸ”— Specific Connectable**: [[keywords/Antibody-Antigen Complexes|Antibody-Antigen Complexes]]
**âš¡ Unique Technical**: [[keywords/Sequence-Structure Generative Model|Sequence-Structure Generative Model]], [[keywords/Iterative Antibody Optimization|Iterative Antibody Optimization]], [[keywords/Guided Sampling|Guided Sampling]]

## ğŸ“‹ ì €ì ì •ë³´

**Authors:** 

## ğŸ“„ Abstract (ì›ë¬¸)

arXiv:2509.16357v1 Announce Type: new 
Abstract: Therapeutic antibody candidates often require extensive engineering to improve key functional and developability properties before clinical development. This can be achieved through iterative design, where starting molecules are optimized over several rounds of in vitro experiments. While protein structure can provide a strong inductive bias, it is rarely used in iterative design due to the lack of structural data for continually evolving lead molecules over the course of optimization. In this work, we propose a strategy for iterative antibody optimization that leverages both sequence and structure as well as accumulating lab measurements of binding and developability. Building on prior work, we first train a sequence-structure diffusion generative model that operates on antibody-antigen complexes. We then outline an approach to use this model, together with carefully predicted antibody-antigen complexes, to optimize lead candidates throughout the iterative design process. Further, we describe a guided sampling approach that biases generation toward desirable properties by integrating models trained on experimental data from iterative design. We evaluate our approach in multiple in silico and in vitro experiments, demonstrating that it produces high-affinity binders at multiple stages of an active antibody optimization campaign.

## ğŸ“ ìš”ì•½

ì´ ë…¼ë¬¸ì€ ì¹˜ë£Œìš© í•­ì²´ í›„ë³´ë¬¼ì§ˆì˜ ìµœì í™”ë¥¼ ìœ„í•œ ìƒˆë¡œìš´ ë°˜ë³µì  ì„¤ê³„ ì „ëµì„ ì œì•ˆí•©ë‹ˆë‹¤. ê¸°ì¡´ì˜ ë°˜ë³µì  ì„¤ê³„ëŠ” êµ¬ì¡°ì  ë°ì´í„°ì˜ ë¶€ì¡±ìœ¼ë¡œ ì¸í•´ ë‹¨ë°±ì§ˆ êµ¬ì¡°ë¥¼ ì˜ í™œìš©í•˜ì§€ ëª»í–ˆìœ¼ë‚˜, ë³¸ ì—°êµ¬ëŠ” í•­ì²´-í•­ì› ë³µí•©ì²´ì˜ ì„œì—´ê³¼ êµ¬ì¡°, ì‹¤í—˜ì  ë°ì´í„°ë¥¼ í™œìš©í•œ ëª¨ë¸ì„ ê°œë°œí–ˆìŠµë‹ˆë‹¤. ì´ ëª¨ë¸ì€ í•­ì²´-í•­ì› ë³µí•©ì²´ì— ëŒ€í•œ ì„œì—´-êµ¬ì¡° í™•ì‚° ìƒì„± ëª¨ë¸ì„ ê¸°ë°˜ìœ¼ë¡œ í•˜ë©°, ì‹¤í—˜ ë°ì´í„°ë¥¼ í†µí•©í•´ ë°”ëŒì§í•œ íŠ¹ì„±ì„ ê°–ì¶˜ í•­ì²´ë¥¼ ìƒì„±í•©ë‹ˆë‹¤. ì—¬ëŸ¬ ì‹¤í—˜ì„ í†µí•´ ì´ ì ‘ê·¼ë²•ì´ ë†’ì€ ì¹œí™”ë ¥ì„ ê°€ì§„ ê²°í•©ì²´ë¥¼ íš¨ê³¼ì ìœ¼ë¡œ ìƒì„±í•¨ì„ ì…ì¦í–ˆìŠµë‹ˆë‹¤.

## ğŸ¯ ì£¼ìš” í¬ì¸íŠ¸

- 1. ì¹˜ë£Œìš© í•­ì²´ í›„ë³´ë¬¼ì§ˆì€ ì„ìƒ ê°œë°œ ì „ì— ê¸°ëŠ¥ì  ë° ê°œë°œ ê°€ëŠ¥ì„±ì˜ ì£¼ìš” íŠ¹ì„±ì„ ê°œì„ í•˜ê¸° ìœ„í•´ ê´‘ë²”ìœ„í•œ ì—”ì§€ë‹ˆì–´ë§ì´ í•„ìš”í•˜ë‹¤.
- 2. ë³¸ ì—°êµ¬ì—ì„œëŠ” í•­ì²´-í•­ì› ë³µí•©ì²´ì— ì‘ìš©í•˜ëŠ” ì‹œí€€ìŠ¤-êµ¬ì¡° í™•ì‚° ìƒì„± ëª¨ë¸ì„ í™œìš©í•˜ì—¬ í•­ì²´ ìµœì í™”ë¥¼ ìœ„í•œ ì „ëµì„ ì œì•ˆí•œë‹¤.
- 3. ì‹¤í—˜ ë°ì´í„°ë¥¼ ê¸°ë°˜ìœ¼ë¡œ í›ˆë ¨ëœ ëª¨ë¸ì„ í†µí•©í•˜ì—¬ ë°”ëŒì§í•œ íŠ¹ì„±ìœ¼ë¡œ ìƒì„± í¸í–¥ì„ ìœ ë„í•˜ëŠ” ê°€ì´ë“œ ìƒ˜í”Œë§ ì ‘ê·¼ë²•ì„ ì„¤ëª…í•œë‹¤.
- 4. ì œì•ˆëœ ë°©ë²•ì€ ì—¬ëŸ¬ ë‹¨ê³„ì˜ í•­ì²´ ìµœì í™” ìº í˜ì¸ì—ì„œ ë†’ì€ ì¹œí™”ë ¥ì˜ ê²°í•©ì²´ë¥¼ ìƒì„±í•¨ì„ ì…ì¦í•˜ì˜€ë‹¤.


---

*Generated on 2025-09-24 01:35:07*